EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials

Khalid M Dousa iD, Eunjeong Shin, Sebastian G Kurz, Eric J Rubin iD, Steven M Holland, Kenneth N Olivier, Charles L Daley iD, Barry N Kreiswirth iD, Paul S Pottinger iD, Robert A Bonomo iD

Clinical Infectious Diseases · 09.02.2026 · 82 (1) · e135-e145

DOI: 10.1093/cid/ciaf547 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, online erschienen am 30.09.2025. Verfasst von Khalid M Dousa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, beta-Lactams, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus (Mab) is a highly drug-resistant non-tuberculous mycobacterium that presents major treatment challenges, particularly in individuals with structural lung disease. Although historically considered ineffective, β-lactam antibiotics have gained renewed attention due to advances in β-lactamase inhibition and cell wall biology. This review synthesizes more than a decade of work, including in vitro susceptibility studies, biochemical characterization of Mab's β-lactamase (BlaMab) and peptidoglycans synthesis, and published clinical cases supporting the potential role of β-lactam-based regimens. We detail the enzymatic pathways involved in peptidoglycan cross-linking and the dual inhibition of D,D- and L,D-transpeptidases by select β-lactams, as well as the functional impact of inhibiting BlaMab. Novel β-lactamase inhibitors such as durlobactam may further enhance β-lactam efficacy. By integrating laboratory insights with clinical experience, this review provides a comprehensive perspective and informs ongoing efforts to design clinical trials repurposing β-lactam/β-lactamase inhibitor combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusbeta-LactamsAnti-Bacterial AgentsMycobacterium Infections, NontuberculousHumansbeta-Lactamase Inhibitorsbeta-LactamasesClinical Trials as TopicMicrobial Sensitivity TestsPeptidoglycanbeta Lactam Antibiotics

Stichwörter der Autor:innen

Mycobacterium abscessusnontuberculous mycobacteria (NTM)novel β-lactam/β-lactamase inhibitor combinationsβ-lactam antibioticsβ-lactamase inhibitors

Substanzen

beta-LactamsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesPeptidoglycanbeta Lactam Antibiotics

Autor:innen und Institutionen

  • Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Division of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachussetts, USA.
  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Khalid M Dousa, Eric J Rubin, Charles L Daley, Barry N Kreiswirth, Paul S Pottinger, Robert A Bonomo

Förderung

  • NIH

Zitieren

APA

Dousa, K. M., Shin, E., Kurz, S. G., Rubin, E. J., Holland, S. M., Olivier, K. N., Daley, C. L., Kreiswirth, B. N., Pottinger, P. S., & Bonomo, R. A. (2026). The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials. Clinical Infectious Diseases, 82(1), e135-e145. https://doi.org/10.1093/cid/ciaf547

Vancouver

Dousa KM, Shin E, Kurz SG, Rubin EJ, Holland SM, Olivier KN, et al. The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials. Clinical Infectious Diseases. 2026;82(1):e135-e145. doi:10.1093/cid/ciaf547

BibTeX
@article{Dousa2026,
  author = {Dousa, Khalid M and Shin, Eunjeong and Kurz, Sebastian G and Rubin, Eric J and Holland, Steven M and Olivier, Kenneth N and Daley, Charles L and Kreiswirth, Barry N and Pottinger, Paul S and Bonomo, Robert A},
  title = {The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {1},
  pages = {e135--e145},
  doi = {10.1093/cid/ciaf547}
}
Kostenlos starten →